Table 1.
Correlation of the clinicopathological finding with IF1 expression in 59 HCC patients with sorafenib therapy.
| Variable | IF1 | P-value | ||
|---|---|---|---|---|
| High expression | Low expression | |||
| Age (year) | ≤50 | 14 | 23 | 0.0150* |
| >50 | 16 | 6 | ||
| Gender | Male | 29 | 28 | 1.0000 |
| Female | 1 | 1 | ||
| HBs antigen | Negative | 5 | 3 | 0.7065 |
| Positive | 25 | 26 | ||
| Liver cirrhosis | Absence | 13 | 15 | 0.6058 |
| Presence | 17 | 14 | ||
| Gamma-glutamytransferase (U/L) | 158.4 | 127.6 | 0.3748 | |
| Serum AFP (ng/ml) | ≤20 | 7 | 1 | 0.0523 |
| >20 | 23 | 28 | ||
| ALT (U/L) | 136.6 | 180.1 | 0.6654 | |
| Tumor multiplicity | Single | 28 | 26 | 0.6707 |
| Multiple | 2 | 3 | ||
| Tumor encapsulation | Absence | 16 | 13 | 0.6058 |
| Presence | 14 | 16 | ||
| Tumor differentiation | II–III | 29 | 28 | 1.0000 |
| IV | 1 | 1 | ||
| Vascular invasion | Absence | 8 | 7 | 0.7611 |
| Presence | 22 | 22 | ||
| Tumor size (cm) | ≤5 | 12 | 16 | 0.6211 |
| >5 | 20 | 19 | ||
| TNM stage | I | 5 | 4 | 0.6531 |
| II | 23 | 21 | ||
| III–IV | 2 | 4 | ||
*
P <0.05.